Results 61 to 70 of about 4,022 (166)

Recurrence of Postneurosurgical Central Nervous System Infection Caused by Acinetobacter baumannii in a Critically Ill Patient Treated With Cefiderocol. A Case Report

Case Reports in Infectious Diseases, Volume 2026, Issue 1, 2026.
Introduction Acinetobacter baumannii (A. baumannii), a gram‐negative bacterium, has become a significant hospital pathogen and the cause of severe nosocomial infections, especially in the intensive care unit (ICU). Bacterial meningitis is a recognized complication that can occur after neurosurgery, and the number of cases of multidrug‐resistant (MDR ...
Giuseppe Accurso, Angelica Ancona, Giovanni Marco Costa, Filippo Vitale, Domenico Petronaci, Giorgia Corpora, Luigi Profera, Antonino Giarratano, Santi Maurizio Raineri, Priya Gusain   +9 more
wiley   +1 more source

Activity of cefiderocol against Pseudomonas aeruginosa from the USA and Europe (2020–2023) with difficult-to-treat resistance phenotype, including those nonsusceptible to recently developed β-lactam/β-lactamase inhibitor combinations: results from the SENTRY antimicrobial surveillance program

Microbiology Spectrum
Cefiderocol and the β-lactam/β-lactamase inhibitor (BL-BLI) combinations ceftazidime-avibactam (CAZ-AVI), imipenem-relebactam (IMI-REL), and ceftolozane-tazobactam (TOL-TAZ) are recommended for the treatment of difficult-to-treat resistance (DTR ...
John H. Kimbrough, Maura H. Karr, Sean T. Nguyen, Boudewijn L. M. DeJonge, Chris Longshaw, Miki Takemura, Yoshinori Yamano, Mariana Castanheira, Rodrigo E. Mendes   +8 more
doaj   +1 more source

A Review of β‐Lactamase Inhibitors in Clinical Use and Development: Mechanisms, Spectrum, and Therapeutic Applications

International Journal of Microbiology, Volume 2026, Issue 1, 2026.
β‐Lactam antibiotics have long served as a cornerstone for treating bacterial infections. However, their widespread and often indiscriminate use has fueled the emergence of multidrug‐resistant Gram‐negative pathogens, primarily through the production and dissemination of β‐lactamase enzymes.
Mohammad Javad Roustaye Gourabi, Anita Nikoo, Bita Khanbabaei, Masoud Kargar, Amirhossein Fayyazi, Seyyed Mohammad Javad Mousavi, Amirhossein Aghdaee, Ali Hashemi, Javad Yasbolaghi Sharahi, Swaran J. S. Flora   +9 more
wiley   +1 more source

Experimental evolution of cefiderocol resistance in Pseudomonas aeruginosa

Heliyon
Cefiderocol is a novel and promising cephalosporin approved for treating severe infections caused by Gram-negative bacteria with limited therapeutic options. One of the primary targets of cefiderocol is Pseudomonas aeruginosa, a significant opportunistic
Igor Chebotar, Konstantin Kuleshov, Julia Bocharova, Nikolay Mayanskiy   +3 more
doaj   +1 more source

Determinants of Antimicrobial Resistance in Acinetobacter baumannii Isolates From Intensive Care Patients in Latvia

International Journal of Microbiology, Volume 2026, Issue 1, 2026.
Background Acinetobacter baumannii is a leading nosocomial pathogen in intensive care units (ICUs), often resistant to multiple antibiotics. Data from the Baltic region remain scarce, limiting infection control and stewardship strategies. Methods We conducted an integrated phenotypic–genotypic analysis of A.
Mihails Dolgusevs, Nityanand Jain, Oksana Savicka, Reinis Vangravs, Jevgenijs Bodrenko, Liene Ostele-Cešķe, Gustavs Rindžs, Dace Zemite, Aigars Reinis, Baiba Rozentale, Divakar Sharma   +10 more
wiley   +1 more source

Biosynthesis of H2S and Siderophores Targeting Gram‐Negative Bacterial Resistance to Reactive Oxygen Species

Advanced Science, Volume 12, Issue 45, December 4, 2025.
Discover how Gram‐negative bacteria develop resistance to reactive oxygen species, and how scientists aim to overcome this challenge. Abstract Reactive oxygen species (ROS) are a promising alternative bactericide. However, it is questioned that bacteria can potentially develop resistance to ROS, similar to their resistance against antibiotics and ...
Congyang Mao, Wanyu Jin, Yiming Xiang, Yizhou Zhu, Jun Wu, Xiangmei Liu, Shuilin Wu, Wei Qiao, Kenneth M. C. Cheung, Kelvin Wai Kwok Yeung   +9 more
wiley   +1 more source

The Efficacy of Topical Cefiderocol Treatment of Experimental Extensively Drug-Resistant Pseudomonas aeruginosa Keratitis Is Dependent upon the State of the Corneal Epithelium

Antibiotics
Background: An overlooked factor in the efficacy of topical antibiotics to treat bacterial keratitis is the state of the corneal epithelium. Recently, we evaluated topical cefiderocol for the treatment of extensively drug-resistant (XDR) Pseudomonas ...
Eric G. Romanowski, Jonathan B. Mandell, Vishal Jhanji, Robert M.Q. Shanks   +3 more
doaj   +1 more source

Treatment of Carbapenem-Resistant Acinetobacter baumannii in Real Life (T-ACI): A Prospective Single-Center Observational Study

Antibiotics
Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) poses significant challenges in healthcare due to its multidrug resistance and high mortality rates among critically ill patients. Results: We enrolled 45 patients.
Antonio Riccardo Buonomo, Riccardo Scotto, Nunzia Esposito, Giulio Viceconte, Nicola Schiano Moriello, Giulia Zumbo, Ilaria Vecchietti, Amedeo Lanzardo, Carmine Iacovazzo, Francesco Curcio, Emanuela Roscetto, Ivan Gentile   +11 more
doaj   +1 more source

When the Trojan horse is unable to reach inside the city: investigation of the mechanism of resistance behind the first reported cefiderocol-resistant E. coli in Canada

Microbiology Spectrum
Gram-negative metallo-β-lactamase-producing bacteria can be extremely problematic, especially when found to be extensively drug-resistant (XDR). Cefiderocol is a novel antimicrobial that has been shown to overcome most carbapenemases, with very rare ...
Kevin R. Barker, Gabriel W. Rebick, Ken Fakharuddin, Clayton MacDonald, Michael R. Mulvey, Laura F. Mataseje   +5 more
doaj   +1 more source

Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study

Infectious Diseases and Therapy
Introduction Cefiderocol is a siderophore cephalosporin showing activity against various carbapenem-resistant Gram-negative bacteria (CR-GNB). No data currently exist about real-world use of cefiderocol in terms of types of therapy (e.g., empirical or ...
Daniele Roberto Giacobbe, Laura Labate, Chiara Russo Artimagnella, Cristina Marelli, Alessio Signori, Vincenzo Di Pilato, Chiara Aldieri, Alessandra Bandera, Federica Briano, Bruno Cacopardo, Alessandra Calabresi, Federico Capra Marzani, Anna Carretta, Annamaria Cattelan, Luca Ceccarelli, Giovanni Cenderello, Silvia Corcione, Andrea Cortegiani, Rosario Cultrera, Francesco Giuseppe De Rosa, Valerio Del Bono, Filippo Del Puente, Chiara Fanelli, Fiorenza Fava, Daniela Francisci, Nicholas Geremia, Lucia Graziani, Andrea Lombardi, Angela Raffaella Losito, Ivana Maida, Andrea Marino, Maria Mazzitelli, Marco Merli, Roberta Monardo, Alessandra Mularoni, Chiara Oltolini, Carlo Pallotto, Emanuele Pontali, Francesca Raffaelli, Matteo Rinaldi, Marco Ripa, Teresa Antonia Santantonio, Francesco Saverio Serino, Michele Spinicci, Carlo Torti, Enrico Maria Trecarichi, Mario Tumbarello, Malgorzata Mikulska, Mauro Giacomini, Anna Marchese, Antonio Vena, Matteo Bassetti, CEFI-SITA investigators   +52 more
doaj   +1 more source